Furthermore, in a mouse AD model, activation of upregulated A2AR can cause the abolishment of long-term synaptic potentiation (LTP) in CA3 pyramidal cells, and A2AR antagonists revert the inhibition of LTP [114], which may provide theoretical support for the treatment of early AD patients. The gene discussed is ADORA2A; the disease is Alzheimer disease.